- Advancing genomic analysis in bioproduction, cell & gene
therapy and drug discovery
- Increased focus on innovation and quality control throughout
the bioproduction cycle
- Launch of AI-powered analysis software and development of
next generation technology platform to accelerate and simplify
large scale genomic analysis
Regulatory News:
Genomic Vision (FR0011799907 – GV, – the “Company”), a
Euronext-listed biotechnology company that develops products and
services for the highly accurate characterization of DNA sequences,
is pleased to provide a business update on its refocused
strategy.
Under new leadership, Genomic Vision is committed to delivering
high-quality genomic solutions that play a critical role in
improving quality control and bioproduction standards, supporting
the development of advanced cell and gene therapies (CGTs). The
Company is focused on leveraging its unique Molecular Combing
Technology (MCT), that offers precise visualization and measurement
of individual DNA molecules, to capitalize on the rapidly growing
demand for highly accurate, fast, and accessible solutions for
genome characterization of advanced therapies at scale. Key areas
of focus include:
- Bioproduction - a complete characterization of genetic material
in line with quality control requirements for biomaterial
production.
- Cell and gene therapy - safety and quality control, and
AI-powered cell line performance prediction to ensure compliance,
de-risk development, shorten timelines, reduce costs and optimize
outcomes.
- Drug discovery - early identification to evaluate the efficacy
of oncology and chemotherapy compounds targeting DNA replication or
repair pathways.
The Company has made encouraging progress towards its strategic
objectives to date, including the development of a next-generation
MCT platform in partnership with Cambridge Consultants. This new
hardware, which relies on miniaturized integrated fluidic
technology, will deliver a more seamless user experience, reduce
MCT analysis turnaround times, automate sample handling and
significantly improve Genomic Vision’s assessing capability. The
Company expects to launch its next-generation technology platform
by the end of 2024, facilitating the transition to a mixed business
model with recurring revenue based on products, consumables and
partnership agreements.
Harnessing the power of Artificial Intelligence (AI), Genomic
Vision is enhancing the precision and scalability of genomic
analysis, accelerating its operations by 30% and reducing error
margins by 50%. FiberSmart® is a data analysis software that uses
advanced AI algorithms for the analysis of Replication Combing
Assays (RCA), an application of MCT. Launched in February 2023,
FiberSmart® was successfully tested and validated by AstraZeneca
(LSE/STO/Nasdaq: AZN), and the Fritz Lipmann Institute, Germany,
and offers notable enhancements in speed and accuracy of data
analysis over existing software solutions while also delivering 95%
accurate AI-powered predictive analytics.
This AI strategy, backed by strategic partnerships, places the
Company at the vanguard of the genomic industry, a global market
expected to reach $62.9 billion by 2028. Genomic Vision’s
forward-looking approach underscores its commitment to lead the
AI-driven genomics revolution, ensuring the Company remains a
frontrunner in this rapidly growing industry. The addressable
market for Genomic Vision technology and services is estimated at
$4.8 billion and growing at two-digit figures compound annual
growth rate.
To expand the potential applications of its DNA analysis
technology further, Genomic Vision initiated a four-year scientific
program in collaboration with the Cancer Research Center of
Marseille. This program, initiated in 2022, focuses on the
development of companion diagnostic tests using Genomic Vision’s
TeloSizer® technology, a novel method for the high-precision
measurement of telomere length and distribution. This technology
has the potential to reveal connections between telomere length and
the onset and severity of diseases such as cancer and
age-associated diseases. The collaboration is ongoing with updates
expected towards the end of the four-year program in 2026.
Alongside next-generation technology developments, Genomic
Vision is increasing engagement with industry and academic
institutions, fostering the development of its platform and
amplifying its reach within the biomanufacturing ecosystem. To this
end, Genomic Vision was pleased to announce that its innovative
technology was confirmed as highly accurate for the quantitative
analysis of genomic events of up to 10 kilobases by the US National
Institute of Standards and Technology (NIST) in February 2023. In
addition to this, the Company became a member of France Biolead
Association in April 2023, providing access to a network of
industry leaders and potential partnering opportunities within the
bioproduction sector.
Aaron Bensimon, Chief Executive Officer of Genomic Vision,
said: “Genomic Vision is committed to delivering high-quality
genomic solutions that enhance the quality control and
bioproduction standards of advanced gene therapies. Through precise
single-molecule DNA visualization and quantification, our molecular
combing technology facilitates the analysis of structural and
functional genome modifications, delivering accurate results for
engineered cell lines. Working together with our partners and
customers, we aim to unlock the full potential of advanced
therapies, with the ultimate goal of empowering breakthroughs in
genomic research and improving patients’ lives.”
Florence Allouche, Chairwoman of Genomic Vision Supervisory
Board, commented: “With our strategic roadmap in place
alongside upcoming next-generation technology developments, Genomic
Vision is well positioned to capitalize on the increasing demand
for targeted advanced therapies in high-growth industries and looks
forward to reporting further progress in the future.”
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company that develops products
and services for the highly accurate characterization of genome
modifications. We deliver high-quality integrated genomic analysis
solutions to improve quality control and bioproduction standards of
advanced gene therapies at scale. Based on molecular combing
technology and artificial intelligence, The Company provides robust
quantitative measurements needed for high confidence
characterization of transformed cell lines and prediction of cell
line performance, in particular in the context of the
biomanufacturing processes of cell and gene therapies. Genomic
Vision’s molecular combing technology has further applications in
drug development of agents targeting DNA replication and damage
response mechanisms, visualizing DNA replication kinetics and
telomere length maintenance. Genomic Vision, based near Paris in
Bagneux, is a public company listed in compartment C of Euronext’s
regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
FORWARD LOOKING STATEMENT
Genomic Vision has set up a financing line in the form of
convertible notes with warrants (OCABSA) with Winance, which does
not intend to remain a shareholder of the company, after receiving
the shares resulting from the conversion or exercise of the
securities.
The shares resulting from the conversion or exercise of the
aforementioned securities will, in general, be sold on the market
very quickly, which is likely to create strong downward pressure on
the share price as well as a strong dilution.
Shareholders could therefore suffer a loss of their invested
capital due to a significant decrease in the value of the company's
shares. The company has carried out several dilutive financing
operations, and investors are advised to be very careful before
making a decision to invest in the company's securities.
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the universal
registration document filed with the AMF on April 28, 2023 under
number D.23-0383, available on the web site of Genomic Vision
(www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230606006040/en/
Genomic Vision Aaron Bensimon Chairman of the Management
Board Tel.: +33 1 49 08 07 51 investisseurs@genomicvision.com
Ulysse Communication Media Relations Bruno Arabian Tél.: +33
1 42 68 29 70 barabian@ulysse-communication.com Consilium
Strategic Communications International Investor Relations &
Strategic Communications Tel.: +44 (0) 20 3709 5700
GenomicVision@consilium-comms.com NewCap France Investor
Relations & Strategic Communications Tel.: +33 1 44 71 94 94
gv@newcap.eu
Guerrero Ventures (TSXV:GV)
過去 株価チャート
から 4 2024 まで 5 2024
Guerrero Ventures (TSXV:GV)
過去 株価チャート
から 5 2023 まで 5 2024